Navigation Links
Novel clinical trial aims to reduce recurrence of aggressive breast cancer
Date:3/8/2011

CLEVELAND In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center are exploring a new method to potentially prevent recurrence of an early stage, aggressive type of breast cancer. The pilot study, conducted by Joe Baar, MD, Director of Breast Cancer Research at UH Case Medical Center's Seidman Cancer Center, is recruiting patients with HER-2 neu+ breast cancer.

Patients with this form of breast cancer typically have a higher recurrence rate of nearly 25% following initial treatment. This novel study aims to improve outcomes through performing bone marrow biopsies to identify if patients' cancer has spread and adding an additional cancer-targeting drug to standard therapy.

"This study has the potential to change the standard of care for women with this type of breast cancer, which tends to spread very quickly," says Dr. Baar, who is also Associate Professor of Medicine at Case Western Reserve University School of Medicine. "A small number of HER-2 neu+ breast cancer patients do not do well following standard therapy. We are hoping to identify these high-risk patients and stop the cancer before it progresses to other parts of the body."

Traditional imaging, such as CT scans and bone scans, does not detect these microscopic metastases, which are small numbers of cancer cells that have spread from the breast to other areas of the body such as the bone marrow. Therefore, patients who are found to have such micrometastases in the bone marrow will receive the cancer-fighting drug Bevacizumab (Avastin) to rid the bone marrow of the micrometastases. The study is funded by Genentech through University Hospitals Case Medical Center.

"This important trial has the potential to really help this subset of women with HER-2 neu+ breast cancer who have a high rate of recurrence," says Stanton Gerson, MD, Director of the UH Seidman Cancer Center and the Case Comprehensive Cancer Center. "This innovative trial has the potential to lay the groundwork for a new standard of care for women with this aggressive form of breast cancer."


'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5158
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. A novel prognostic marker for biliary atresia
2. Genome sequencing used to assess a novel form of Clostridium botulinum
3. Novel mechanism for control of gene expression revealed
4. Novel methods for improved breast cancer survival
5. Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma
6. Novel surgery removes rare tumor, rebuilds trachea
7. Researchers reveal function of novel molecule that underlies human deafness
8. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
9. UCI researchers find novel memory-enhancing mechanism in brain
10. Novel imaging technique may reduce lymphedema in breast cancer patients
11. New standards of care and novel treatment options for several forms of lymphoma unveiled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney ... Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. ... to Highway 121. , As the practice has grown, the need for more space ...
(Date:2/24/2017)... ... 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... generation. Yisrayl makes an astounding statement when he says that the entire Bible ... Bible details the current times so plainly that anyone should be able to see ...
(Date:2/24/2017)... ... 24, 2017 , ... Rosica Communications, a national PR ... media relations, social media, content marketing and SEO, is now offering direct, social ... intuitive marketing automation platform. , Rosica will now offer the platform to its ...
(Date:2/23/2017)... Boston, MA (PRWEB) , ... February 23, 2017 ... ... Education and Department of Justice jointly issued a letter to withdraw ... in accordance with their gender identity. The guidance issued in May 2016 by ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Australia , Feb. 23, 2017  Directors from Pharma To ... two companies have joined forces, resulting in the founding of Pharma ... Pharma To Market are pleased to announce their expansion ... office in Singapore . The company are delighted ... as Co-Director of the Singapore based entity. ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... -- LG Innotek hat heute die weltweit erste 70 mw ... 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C LED ... 280 nm und eignet sich damit für Sterilisationsaufgaben. Es verhindert ... Das Produkt von LG Innotek erzeugt UV-Strahlung im Bereich ... ...
Breaking Medicine Technology: